New pharmaceutical applications for macromolecular binders

Nicolas Bertrand (1) , Marc Gauthier (2) , Céline Bouvet (1) , Pierre Moreau (1) , Anne Petitjean (3) , Jean-Christophe Leroux (2) , Jeanne Leblond (1)

1 UdeM - Université de Montréal
2 D-CHAB - Department of Chemistry and Applied Biosciences [ETH Zürich]
3 Queen's University [Kingston, Canada]

Macromolecular binders consist of polymers, dendrimers, and oligomers with binding properties for endogenous or exogenous substrates. This field, at the frontier of host/guest chemistry and pharmacology, has met a renewed interest in the past decade due to the clinical success of several sequestrants, like sevelamer hydrochloride (Renagel®) or sugammadex (Bridion®). In many instances, multivalent binding by the macromolecular drugs can modify the properties of the substrate, and may prevent it from reaching its site of action and/or trigger a biological response. From small (e.g., ions) to larger substrates (e.g., bacteria and cells), this review presents the state-of-the-art of macromolecular binders and provides detailed illustrative examples of recent developments bearing much promise for future pharmaceutical applications.

Domaines: Polymères; Chimie organique; Sciences pharmaceutiques

Nicolas Bertrand, Marc Gauthier, Céline Bouvet, Pierre Moreau, Anne Petitjean, et al.. New pharmaceutical applications for macromolecular binders. Journal of Controlled Release, 2011, ⟨10.1016/j.jconrel.2011.04.027⟩. ⟨hal-02512499⟩